Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma
Objective: To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles. - Met...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 15, 2017
|
| In: |
Neurology
Year: 2017, Jahrgang: 88, Heft: 15, Pages: 1422-1430 |
| ISSN: | 1526-632X |
| DOI: | 10.1212/WNL.0000000000003809 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1212/WNL.0000000000003809 Verlag, lizenzpflichtig, Volltext: https://n.neurology.org/content/88/15/1422 
|
| Verfasserangaben: | Dorothee Gramatzki, MD, Philipp Kickingereder, MD, Bettina Hentschel, PhD, Jörg Felsberg, MD, Ulrich Herrlinger, MD, Schackert, MD, Jörg-Christian Tonn, MD, Manfred Westphal, MD, Michael Sabel, MD, Uwe Schlegel, MD, Wolfgang Wick, MD, Torsten Pietsch, MD, Guido Reifenberger, MD, Markus Loeffler, MD, Martin Bendszus, MD, Michael Weller, MD, |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1572407174 | ||
| 003 | DE-627 | ||
| 005 | 20220814124257.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180426s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/WNL.0000000000003809 |2 urn | |
| 035 | |a (DE-627)1572407174 | ||
| 035 | |a (DE-576)502407174 | ||
| 035 | |a (DE-599)BSZ502407174 | ||
| 035 | |a (OCoLC)1341007868 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gramatzki, Dorothee |d 1980- |e VerfasserIn |0 (DE-588)132228440 |0 (DE-627)519546520 |0 (DE-576)260858412 |4 aut | |
| 245 | 1 | 0 | |a Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma |c Dorothee Gramatzki, MD, Philipp Kickingereder, MD, Bettina Hentschel, PhD, Jörg Felsberg, MD, Ulrich Herrlinger, MD, Schackert, MD, Jörg-Christian Tonn, MD, Manfred Westphal, MD, Michael Sabel, MD, Uwe Schlegel, MD, Wolfgang Wick, MD, Torsten Pietsch, MD, Guido Reifenberger, MD, Markus Loeffler, MD, Martin Bendszus, MD, Michael Weller, MD, |
| 264 | 1 | |c March 15, 2017 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.08.2021 | ||
| 520 | |a Objective: To explore an association with survival of modifying the current standard of care for patients with newly diagnosed glioblastoma of surgery followed by radiotherapy plus concurrent and 6 cycles of maintenance temozolomide chemotherapy (TMZ/RT → TMZ) by extending TMZ beyond 6 cycles. - Methods: The German Glioma Network cohort was screened for patients with newly diagnosed glioblastoma who received TMZ/RT → TMZ and completed ≥6 cycles of maintenance chemotherapy without progression. Associations of clinical patient characteristics, molecular markers, and residual tumor determined by magnetic resonance imaging after 6 cycles of TMZ with progression-free survival (PFS) and overall survival (OS) were analyzed with the log-rank test. Multivariate analyses using the Cox proportional hazards model were performed to assess associations of prolonged TMZ use with outcome. - Results: Sixty-one of 142 identified patients received at least 7 maintenance TMZ cycles (median 11, range 7-20). Patients with extended maintenance TMZ treatment had better PFS (20.5 months, 95% confidence interval [CI] 17.7-23.3, vs 17.2 months, 95% CI 10.2-24.2, p = 0.035) but not OS (32.6 months, 95% CI 28.9-36.4, vs 33.2 months, 95% CI 25.3-41.0, p = 0.126). However, there was no significant association of prolonged TMZ chemotherapy with PFS (hazard ratio [HR] = 0.8, 95% CI 0.4-1.6, p = 0.559) or OS (HR = 1.6, 95% CI 0.8-3.3, p = 0.218) adjusted for age, extent of resection, Karnofsky performance score, presence of residual tumor, O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status, or isocitrate dehydrogenase (IDH) mutation status. - Conclusion: These data may not support the practice of prolonging maintenance TMZ chemotherapy beyond 6 cycles. - Classification of evidence: This study provides Class III evidence that in patients with newly diagnosed glioblastoma, prolonged TMZ chemotherapy does not significantly increase PFS or OS. | ||
| 700 | 1 | |a Vollmuth, Philipp |d 1987- |e VerfasserIn |0 (DE-588)1043270086 |0 (DE-627)771319177 |0 (DE-576)394600738 |4 aut | |
| 700 | 1 | |a Hentschel, Bettina |d 1963- |e VerfasserIn |0 (DE-588)172924758 |0 (DE-627)697852199 |0 (DE-576)13377919X |4 aut | |
| 700 | 1 | |a Felsberg, Jörg |d 1969- |e VerfasserIn |0 (DE-588)120103788 |0 (DE-627)080448852 |0 (DE-576)292043708 |4 aut | |
| 700 | 1 | |a Herrlinger, Ulrich |e VerfasserIn |0 (DE-588)1130709655 |0 (DE-627)88507307X |0 (DE-576)486968480 |4 aut | |
| 700 | 1 | |a Schmitz-Schackert, Gabriele |e VerfasserIn |0 (DE-588)1084219565 |0 (DE-627)848456440 |0 (DE-576)456233458 |4 aut | |
| 700 | 1 | |a Tonn, Jörg-Christian |d 1958- |e VerfasserIn |0 (DE-588)110843843 |0 (DE-627)392381001 |0 (DE-576)18699074X |4 aut | |
| 700 | 1 | |a Westphal, Manfred |d 1955- |e VerfasserIn |0 (DE-588)1028398166 |0 (DE-627)730651584 |0 (DE-576)375928790 |4 aut | |
| 700 | 1 | |a Sabel, Michael |d 1965- |e VerfasserIn |0 (DE-588)112035417X |0 (DE-627)873317270 |0 (DE-576)480301409 |4 aut | |
| 700 | 1 | |a Schlegel, Uwe |d 1958- |e VerfasserIn |0 (DE-588)138542686 |0 (DE-627)603798632 |0 (DE-576)307985717 |4 aut | |
| 700 | 1 | |a Wick, Wolfgang |d 1970- |e VerfasserIn |0 (DE-588)120297736 |0 (DE-627)080586929 |0 (DE-576)186221320 |4 aut | |
| 700 | 1 | |a Pietsch, Torsten |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reifenberger, Guido |e VerfasserIn |0 (DE-588)1082574740 |0 (DE-627)847675068 |0 (DE-576)455525382 |4 aut | |
| 700 | 1 | |a Löffler, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bendszus, Martin |e VerfasserIn |0 (DE-588)1032676426 |0 (DE-627)738634131 |0 (DE-576)175567697 |4 aut | |
| 700 | 1 | |a Weller, Michael |d 1962- |e VerfasserIn |0 (DE-588)130838039 |0 (DE-627)506356701 |0 (DE-576)29836834X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology |d Philadelphia, Pa. : Wolters Kluwer, 1951 |g 88(2017), 15, Seite 1422-1430 |h Online-Ressource |w (DE-627)302718524 |w (DE-600)1491874-2 |w (DE-576)079876609 |x 1526-632X |7 nnas |a Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma |
| 773 | 1 | 8 | |g volume:88 |g year:2017 |g number:15 |g pages:1422-1430 |g extent:9 |a Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma |
| 856 | 4 | 0 | |u https://doi.org/10.1212/WNL.0000000000003809 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://n.neurology.org/content/88/15/1422 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210818 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1032676426 |a Bendszus, Martin |m 1032676426:Bendszus, Martin |d 910000 |d 911100 |e 910000PB1032676426 |e 911100PB1032676426 |k 0/910000/ |k 1/910000/911100/ |p 15 | ||
| 998 | |g 120297736 |a Wick, Wolfgang |m 120297736:Wick, Wolfgang |d 910000 |d 911100 |e 910000PW120297736 |e 911100PW120297736 |k 0/910000/ |k 1/910000/911100/ |p 11 | ||
| 998 | |g 1043270086 |a Vollmuth, Philipp |m 1043270086:Vollmuth, Philipp |d 910000 |d 911100 |d 50000 |e 910000PV1043270086 |e 911100PV1043270086 |e 50000PV1043270086 |k 0/910000/ |k 1/910000/911100/ |k 0/50000/ |p 2 | ||
| 999 | |a KXP-PPN1572407174 |e 3969784654 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"March 15, 2017"}],"relHost":[{"recId":"302718524","physDesc":[{"extent":"Online-Ressource"}],"disp":"Limited role for extended maintenance temozolomide for newly diagnosed glioblastomaNeurology","pubHistory":["1.1951 -"],"origin":[{"publisher":"Wolters Kluwer ; Ovid ; Lippincott Williams & Wilkins","publisherPlace":"Philadelphia, Pa. ; [Erscheinungsort nicht ermittelbar] ; Hagerstown, Md.","dateIssuedKey":"1951","dateIssuedDisp":"1951-"}],"title":[{"subtitle":"official journal of the American Academy of Neurology","title_sort":"Neurology","title":"Neurology"}],"part":{"pages":"1422-1430","issue":"15","extent":"9","text":"88(2017), 15, Seite 1422-1430","year":"2017","volume":"88"},"id":{"zdb":["1491874-2"],"issn":["1526-632X"],"eki":["302718524"]},"note":["Gesehen am 12.12.23"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"}}],"person":[{"family":"Gramatzki","role":"aut","given":"Dorothee","display":"Gramatzki, Dorothee"},{"display":"Vollmuth, Philipp","family":"Vollmuth","role":"aut","given":"Philipp"},{"given":"Bettina","role":"aut","family":"Hentschel","display":"Hentschel, Bettina"},{"display":"Felsberg, Jörg","family":"Felsberg","role":"aut","given":"Jörg"},{"family":"Herrlinger","given":"Ulrich","role":"aut","display":"Herrlinger, Ulrich"},{"role":"aut","given":"Gabriele","family":"Schmitz-Schackert","display":"Schmitz-Schackert, Gabriele"},{"display":"Tonn, Jörg-Christian","family":"Tonn","role":"aut","given":"Jörg-Christian"},{"given":"Manfred","role":"aut","family":"Westphal","display":"Westphal, Manfred"},{"display":"Sabel, Michael","given":"Michael","role":"aut","family":"Sabel"},{"family":"Schlegel","given":"Uwe","role":"aut","display":"Schlegel, Uwe"},{"display":"Wick, Wolfgang","family":"Wick","role":"aut","given":"Wolfgang"},{"family":"Pietsch","role":"aut","given":"Torsten","display":"Pietsch, Torsten"},{"family":"Reifenberger","given":"Guido","role":"aut","display":"Reifenberger, Guido"},{"display":"Löffler, Markus","role":"aut","given":"Markus","family":"Löffler"},{"role":"aut","given":"Martin","family":"Bendszus","display":"Bendszus, Martin"},{"display":"Weller, Michael","given":"Michael","role":"aut","family":"Weller"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 18.08.2021"],"title":[{"title":"Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma","title_sort":"Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma"}],"physDesc":[{"extent":"9 S."}],"recId":"1572407174","name":{"displayForm":["Dorothee Gramatzki, MD, Philipp Kickingereder, MD, Bettina Hentschel, PhD, Jörg Felsberg, MD, Ulrich Herrlinger, MD, Schackert, MD, Jörg-Christian Tonn, MD, Manfred Westphal, MD, Michael Sabel, MD, Uwe Schlegel, MD, Wolfgang Wick, MD, Torsten Pietsch, MD, Guido Reifenberger, MD, Markus Loeffler, MD, Martin Bendszus, MD, Michael Weller, MD,"]},"id":{"eki":["1572407174"],"uri":["10.1212/WNL.0000000000003809"]}} | ||
| SRT | |a GRAMATZKIDLIMITEDROL1520 | ||